Product
HYQVIA
Aliases
IGI 10% with rHuPH20, Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase, Immune Globulin Infusion (Human), 10% Solution with rHuPH20.
Name
Octagam Immune Globulin (Human)
INN Name
Immune Globulin
FDA Approved
Yes
6 clinical trials
1 organization
3 indications
1 document
Indication
Healthy Control ParticipantsIndication
Primary Immunodeficiency DiseasesClinical trial
A Phase 1, Open-Label, Randomized Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-Up and No Ramp-Up Dosing in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2022-03-02
Clinical trial
Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in Primary Immunodeficiency Diseases (PIDD)Status: Recruiting, Estimated PCD: 2026-02-10
Clinical trial
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency DiseasesStatus: Completed, Estimated PCD: 2021-01-15
Clinical trial
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Status: Completed, Estimated PCD: 2023-07-04
Clinical trial
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)Status: Completed, Estimated PCD: 2021-10-21
Clinical trial
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency DiseasesStatus: Completed, Estimated PCD: 2022-07-20